Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

A Prospective, Multicenter, Randomized Controlled Phase II Study to Evaluate the Efficacy and Safety of Adebrelimab Combined with Chemotherapy with or without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

NCT Number	NCT06908668
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions	HER2-Negative Locally Advanced Breast Cancer
Enrollment	170 participants
Start Date	2025-03-31
Primary Completion	2028-09-10 (estimated)
Study Completion	2028-09-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-10